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Abstract
The nucleus accumbens (NAC) plays a key role in directing appropriate motor output following the presentation of behaviorally
relevant stimuli. As such, we postulate that accumbens efferents also participate in the modulation of neuronal circuits regulating
attentional processes directed toward the identification and selection of these stimuli. In this study, N-methyl-d-aspartate (NMDA)
and D1 ligands were perfused into the shell region of the NAC of awake rats. Cortical cholinergic transmission, a mediator of
attentional processes, was measured via microdialysis probes inserted into the prefrontal cortex (PFC). NMDA perfusions (150 or
250 lm) into NAC resulted in significant increases in acetylcholine (ACh) efflux in PFC (150–200% above baseline levels).
Co-administration of the D1 antagonist SCH-23390 (150 lm) markedly attenuated (by approx. 70%) ACh efflux following perfusions
of 150 lm NMDA but not following 250 lm NMDA, suggesting that D1 receptor activity contributes to the ability of the lower but not
the higher concentration of NMDA to increase cortical ACh release. Collectively, these data reveal a positive modulation of NMDA
receptors by D1 receptors in NAC that is expressed trans-synaptically at the level of cortical transmission. This modulation may
underlie the coordinated linking of attentional processes and motor output following exposure to salient and behaviorally relevant
stimuli.
Introduction
The nucleus accumbens (NAC) has long been recognized in its role as
an interface between limbic input and motor output (Mogenson et al.,
1980; Mogenson & Yang, 1991; Pennartz et al., 1994; Kelley, 1999).
Consistent with this role, more recent functional characterizations of
the NAC have focused on the selection of appropriate behaviors in
response to novel (Rebec et al., 1997; Legault & Wise, 1999) and
discriminative cues with incentive salience (Berridge & Robinson,
1998; Neigh et al., 2004; Nicola et al., 2004a,b; Yun et al., 2004a,b).
This linking of motor responses to cues that predict reward is a central
feature of motivated behavior.
Recent studies have focused on the role of the NAC in directing the
activity of various ensembles of projection neurons to direct motor
responses following the presentation of cues that predict reward (Schultz
et al., 2003; Deadwyler et al., 2004; Ghitza et al., 2004). Far less effort,
however, has been directed toward the NAC’s modulation of neuronal
circuits contributing to the attentional processing of these discriminative
cues. Through experience animals become biased to direct their limited
attentional resources toward the identification, selection and processing
of stimuli that are novel or have acquired incentive salience (Franken,
2003; Sarter et al., 2003; Dalley et al., 2004a).
The basal forebrain cortical cholinergic system has been repeatedly
demonstrated to play a key role in the mediation of attentional
processing. Administration of muscarinic antagonists results in
performance deficits on tasks that require attentional processing in
humans (Mauri et al., 1994; Koller et al., 2003) and laboratory
animals (Chudasama et al., 2004; Chen et al., 2004). Selective lesions
of cholinergic inputs to cortex impair the performance of tasks that
explicitly tax sustained and visuo-spatial attention in laboratory
animals (McGaughy et al., 1996; Dalley et al., 2004b). Moreover,
performance of these tasks is sufficient to increase the release of
acetylcholine (ACh) in cortical regions (prefrontal and parietal) known
to play key roles in the mediation of attentional processing
(Himmelheber et al., 2000; Passetti et al., 2000; Dalley et al., 2001;
Arnold et al., 2002). Recently, we have demonstrated that the
magnitude of this stimulation in cortical ACh release is proportional to
the degree of cognitive effort exerted in the performance of a sustained
attention task (Kozak et al., 2005). Finally, a growing number of
studies have reported improvements in attentional processing follow-
ing nicotinic receptor agonists that, among other things, increase
cortical cholinergic activity (Hahn et al., 2003; Kumari et al., 2003).
The NAC is one of several input structures that play a key role in
regulating the excitability of the basal forebrain and hence cortical
ACh release. Anatomically, c-aminobutyric acid (GABA)ergic pro-
jections from the NAC terminate on cholinergic neurons within the
basal forebrain (Zaborszky & Cullinan, 1992), and GABAA receptor
activity within basal forebrain affects cortical ACh release (Moore
et al., 1992). Our laboratory has conducted a series of studies
demonstrating the effect of various transmitter manipulations in NAC
on cortical ACh release. First, perfusion of N-methyl-d-aspartate
(NMDA), AMPA or non-selective glutamate antagonists into the shell
regions of the NAC was sufficient to stimulate ACh release in
prefrontal cortex (PFC; Neigh-McCandless et al., 2002). Second,
perfusion of D2, but not D1, antagonists into the NAC shell was
sufficient to block the stimulation of cortical ACh release seen
following systemic administration of a benzodiazepine-selective
partial inverse agonist (Moore et al., 1999). Finally, performance in
a task in which consumption of a mildly aversive liquid became a
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discriminative cue for access to a highly palatable cheese treat
markedly increased cortical ACh release, and this stimulated release
was attenuated following perfusion of tetrodotoxin (TTX) into the
shell region of the NAC (Neigh et al., 2004).
The convergence of glutamatergic and dopaminergic inputs on
medium spiny GABAergic projections of NAC provides a chemoan-
atomical substrate for understanding the linking of discriminative cues
with motor output. Glutamate inputs from PFC, amygdala and
hippocampus are involved in distinguishing between different dis-
criminative cues (Schoenbaum et al., 1998; 1999). Dopaminergic
inputs from ventral tegmental area (VTA) are activated following
novel or salient stimuli (Legault & Wise, 1999; Rebec et al., 1997),
particularly those cues that predict reward (Schultz et al., 2003; Nicola
et al., 2004a,b). The interaction of these inputs has been best conveyed
in theories speculating that dopamine selectively gates the cortico-
limbic inputs to NAC medium spiny neurons and results in the biasing
toward certain behavioral responses at the expense of others (Pennartz
et al., 1994; Nicola et al., 2004a,b; Yun et al., 2004a,b).
Guided by recent demonstrations of NAC glutamate–dopamine
gating of cue-evoked goal-directed behavior (Yun et al., 2004a,b) and
the clear anatomical and functional links between NAC efferents and
the basal forebrain, we tested the hypothesis that NAC glutamate
and dopamine receptor activity would modulate cortical ACh release.
Such modulation would direct the recruitment of attentional resources,
necessary for the coordinated interplay between discriminative cues in
the environment and the appropriate behavioral response. More
specifically, we determined whether NMDA perfusions into the NAC
shell would affect cortical ACh release and, if so, whether D1 receptor
activity positively modulates this effect as has been shown at several
other levels of analysis (Snyder et al., 1998; O’Donnell, 1999; Vezina
& Kim, 1999; Goto & O’Donnell, 2001b). In these experiments,
different concentrations of NMDAwere perfused into the shell region
of the NAC, and changes in cortical ACh efflux were measured. The
modulation of this effect by D1 receptors was assessed by studying the
effects of NMDA co-administered with the D1 antagonist SCH-23390.
Materials and methods
Subjects
Male Fisher 344 ⁄Brown Norway F1 rats (Harlan Sprague–Dawley,
Indianapolis, IN, USA) weighing between 300 and 400 g were utilized
for all studies. Animals were maintained in a temperature- and
humidity-controlled room on a 12 : 12 h light : dark cycle (lights on:
06.30 h) and individually housed in plastic cages lined with corn cob
bedding (Harlan Teklad, Madison, WI, USA). Animals had access to
food and water ad libitum. All procedures involving animals were
approved by The Ohio State University Institutional Animal Care and
Use Committee in accordance with the NIH Guide for the Care and
Use of Laboratory Animals.
Three days prior to surgery, animals were acclimated to the
microdialysis testing environment in clear plastic bowls (35 cm
height · 38 cm diameter; CMA, Stockholm, Sweden) lined with corn
cob bedding. Animals remained in the bowls for a minimum of
4 h ⁄ day, and returned to their home cages at the end of each
acclimation period.
Surgery
Following their 3 days of acclimation, animals were anesthetized
using isoflurane gas (2%, 0.6 L ⁄min, O2 delivery) and unilaterally
implanted with microdialysis guide cannulae (0.38 mm o.d.; Sci Pro,
Sanborn, NY, USA) into the medial prefrontal cortex (mPFC; in mm
from bregma: AP +4.2, ML ± 0.6, DV )0.6 with the guide tip at 20 
rostral) and ipsilateral NAC shell (NAC; in mm from bregma: AP
+1.3, ML ± 1.0, DV )5.8). The PFC was selected because its role in
the top-down regulation of attentional processing (see Sarter et al.,
2001) suggests that it should be affected by motivational factors
mediated by mesolimbic regions such as the NAC. The shell region of
the NAC was selected because it (as opposed to the NAC core)
projects directly to the cholinergic-rich areas of the basal forebrain
(Zaborszky & Cullinan, 1992). Coordinates were determined from the
atlas of Paxinos & Watson (1998). Hemispheres were counterbalanced
in each experiment. Cannulae were inserted with dummy stylets to
prevent occlusion, and were fixed using dental cement and three
stainless steel skull screws. Animals received a prophylactic dose of
the antibiotic amoxicillin (100 mg ⁄ kg) subcutaneously, and the
surgical site was swabbed with a topical antibiotic ointment (lidocaine,
5%). Animals were allowed to recover for 3 days following surgery
while continuing to be acclimated daily to the testing environment.
General microdialysis procedures
Microdialysis sessions were conducted using repeated perfusions, with
each animal receiving three different pharmacological manipulations,
one every other day. This repeated testing paradigm has the advantage
of decreasing variability among treatment conditions because each
subject is able to serve as his own control. Furthermore, it allows for
paradigms such as dose–response analyses, as well as agonist–
antagonist interactions to be studied in the same animal. The
procedure has been repeatedly validated by demonstrating that basal
cortical ACh efflux does not significantly change over repeated
dialysis sessions, and that the effects of behavioral, pharmacological
or sensory manipulations on ACh levels do not interact with dialysis
sessions (Bruno et al., 1999; Nelson et al., 2002).
On the fourth day following surgery, animals were brought to the
testing environment and allowed to acclimate for 30 min prior to
insertion of microdialysis probes. Following the 30-min acclimation
period, stylets were removed and probes (Sci Pro, 0.2 mm o.d., 3 mm
membrane tip for mPFC, 0.2 mm o.d., 2.0 mm membrane tip for
NAC) were inserted into each guide.
Probes were continuously perfused with artificial cerebral spinal
fluid (aCSF) (containing, in mm: NaCl, 166.5; NaHCO3, 27.5; KCl,
2.4; CaCl2, 1.2; Na2SO4, 0.5; KH2PO4, 0.5; glucose, 1.0, pH 6.8) at a
flow rate of 1.25 lL ⁄min. This perfusion medium did not contain an
acetylcholinesterase inhibitor. A 3-h washout period was observed
after probe insertion to allow ACh efflux to reach a stable baseline that
was maximally sensitive to TTX before beginning collections (Moore
et al., 1992). Three distinct experiments were conducted using this
general paradigm; they are described in detail as follows.
The concentrations of NMDA and SCH-23390 utilized in these
microdialysis experiments were selected from a review of several
studies in the literature. Local perfusions of NMDA, via reverse
dialysis, in concentrations of 100–500 lm NMDA produced concen-
tration-dependent changes in basal and stress-induced dopamine
release in PFC (Del Arco & Mora, 2001; Lorrain et al., 2003). Thus,
we chose to study two concentrations of NMDA, 150 and 250 lM,
which were in a range shown to have effects on forebrain
neurochemistry. Likewise, intrahippocampal perfusions of SCH-
23390 (100–250 lm) attenuated NMDA-induced locomotion and
dopamine release (Zornoza et al., 2005), whereas intrastriatal perfu-
sions of SCH-23390 (10 lm) attenuated NMDA-induced increases in
glutamate release in substantia nigra (Marti et al., 2002). Thus, our
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selection of 150 lm SCH-23390 was within the range of concentra-
tions known to attenuate certain actions of NMDA.
Experiment 1: the effects of a D1 antagonist on the lower
concentration of NMDA
Animals (n ¼ 8) were tested three times, with a different pharmaco-
logical manipulation (vehicle–aCSF, 150 lm NMDA, or 150 lm
SCH-23390 + 150 lm NMDA) administered, in counterbalanced
order, every other day. Following the 3-h washout period, four
baseline samples were collected; 15-min collection intervals were
observed with all time points. Following the four baseline collections,
the syringe was switched from aCSF to one containing aCSF + the D1
antagonist, SCH-23390 (aCSF was perfused for an additional two
collections in the vehicle and NMDA sessions). Following a 15-min
washout, two additional collections of either aCSF or aCSF + antag-
onist were taken. The syringe was then switched to one containing
aCSF + drug (150 lm NMDA, 150 lm SCH-23390 + 150 lm
NMDA, or aCSF vehicle). Following a 15-min washout, four
additional collections were taken before switching the syringe back
to one containing only aCSF. This perfusion lasted a total of 60 min,
including an initial 15-min washout period. Following the last
collection, probes were removed and stylets were reinserted before
returning animals to their home cages. A separate group of rats
(n ¼ 4) was tested once and served as timed-controls for the effects of
the D1 antagonist over the entire interval in which NMDAwould have
been perfused. In this group, SCH-23390 (150 lm) was perfused after
the fourth baseline collection until the time at which drugs are
typically removed and aCSF was re-introduced.
Experiment 2: the effects of a D1 antagonist on the higher
concentration of NMDA
Animals (n ¼ 9) were tested three times, with a different pharmaco-
logical manipulation (vehicle–aCSF, 250 lm NMDA, or 150 lm
SCH-23390 + 250 lm NMDA) administered, in counterbalanced
order, every other day. Following the 3-h washout period, four
baseline samples were collected; 15-min collection intervals were
observed with all time points. Following the four baseline collections,
the syringe was switched from aCSF to one containing aCSF + the
antagonist, SCH-23390 (aCSF was perfused for an additional two
collections in the vehicle and NMDA sessions). Following a 15-min
washout, two additional collections of either aCSF or aCSF + antag-
onist were taken. The syringe was then switched to one containing
aCSF + drug (150 lm NMDA, 150 lm SCH-23390 + 150 lm
NMDA, or aCSF vehicle). Following a 15-min washout, four
additional collections were taken before switching back to one
containing only aCSF. This perfusion lasted a total of 60 min,
including an initial 15-min washout period. Following the last
collection, probes were removed and stylets were reinserted before
returning animals to their home cages. A separate group of rats
(n ¼ 4) was tested once and served as timed-controls for the effects of
the D1 antagonist over the entire interval in which NMDAwould have
been perfused. In this group, SCH-23390 (150 lm) was perfused after
the fourth baseline collection until the time at which drugs are
typically removed and aCSF was re-introduced.
HPLC analysis
Dialysis samples were stored at )80 C until analysed using high-
performance liquid chromatography (HPLC) with electrochemical
detection. A volume of 15 lL of each sample was injected by an
autosampler (ESA, Chelmsford, MA, USA). ACh and choline were
separated by a C-18 polymer column (ESA; 250 · 3 mm) using a
sodium phosphate mobile phase (in mm: Na2HPO4, 100.0; TMACl,
0.5; 1-octanesulphonic acid, 2.0; 0.005% microbicide reagent MB,
pH ¼ 8.0; flow rate of 0.5 mL ⁄min). A pre-column immobilized
enzyme reactor (IMER; ESA) was utilized to hydrolyse choline,
allowing for greater separation between choline and ACh peaks. ACh
and choline were then hydrolysed post-column by an additional
enzyme reactor (ESA), converted to H2O2 (Potter et al., 1983), and
quantified using a peroxidase-wired ceramic glassy carbon electrode
(Model #5041 microdialysis analytical cell, ESA), with an applied
potential of )200 mV (Huang et al., 1995). The detection limit under
these conditions was approximately 1.0 fmol ⁄ 15 lL injection.
Histology
Following the final microdialysis session, animals were given an
overdose of sodium pentobarbital and transcardially perfused with
0.9% heparinized saline followed by 10% formalin. Brains were
removed and stored in 10% formalin for 24 h then transferred to a
30% sucrose solution for at least 3 days. Brains were sectioned using a
cryostat; 50-lm sections were mounted on slides, stained using Cresyl
violet, and examined under a light microscope. Subjects whose probe
placements were located outside of either the mPFC or NAC shell
were excluded from further analysis.
Data analysis
For each experiment, changes in basal ACh efflux (fmol ⁄ 15 lL)
across sessions and treatment groups were analysed using one-way
repeated-measures analyses of variance (anovas). Basal efflux was
then defined as the mean of the four baseline collections, and
subsequent data were expressed as percent change from that mean
baseline. Statistical analyses of drug effects were conducted using a
two-way, within-subjects anova with drug GROUP and TIME as
within-subjects measures. Two-way anovas were utilized to examine
differences between specific treatment groups where appropriate. One-
way anovas were also used to determine the time that post-drug ACh
efflux levels returned to baseline where appropriate. A minimum
number of t-tests was also utilized to examine differences between
drug conditions at specific time points. Significance was defined as
P < 0.05, and the Huynh–Feldt correction was utilized to reduce Type
1 errors associated with repeated-measures anovas (Vasey & Thayer,




Figure 1 shows representative placements of these areas. Any animals
whose probe placements fell outside the mPFC and ⁄ or the NAC shell
were excluded from further analysis.
Experiment 1: the effects of a D1 antagonist on a moderate
concentration of NMDA
This experiment examined the contribution of D1 receptor activity to
the ability of a moderate concentration of NMDA to stimulate cortical
ACh release. Figure 2 illustrates the effects of aCSF vehicle, 150 lm
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Fig. 1. (A) A schematic representation of a mPFC probe placement. Guides were implanted so that when probes were inserted, the membrane tip (3.0 mm) was
located at: AP +4.2, ML ± 0.6, DV )0.6 from dura at 20  rostral. (B) A photomicrograph from one of the subjects that is representative of the mPFC placement
illustrated in (A). The arrow indicates the end of the guide cannula; the probe extends 3 mm beyond that point. (C) A schematic representation of a NAC shell probe
placement. Guides were implanted so that when probes were inserted (2.0 mm active tip) the membrane tip was located at AP +1.3, ML ± 1.0, DV )5.8 from dura
matter. (D) A photomicrograph from a NAC shell placement. The area between the arrows represents the active membrane tip. All of the above coordinates were
calculated according to Paxinos & Watson (1998).
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NMDA and 150 lm SCH-23390 + 150 lm NMDA on cortical ACh
efflux (n ¼ 8). Basal levels of efflux were stable over the three
dialysis SESSIONs (F2,16 ¼ 3.244, P ¼ 0.07), and across the three
treatment GROUPs (F2,16 ¼ 0.546, P ¼ 0.591), as revealed by one-
way anovas. Basal levels of ACh (mean ± SEM, fmol ⁄ 15 lL) were
6.9 ± 2.6, 4.4 ± 1.2 and 5.9 ± 1.5 for aCSF, 150 lm NMDA, and
150 lm SCH-23390 + 150 lm NMDA sessions, respectively. Given
that basal levels of ACh efflux did not differ over session or group, all
subsequent values were expressed and analysed as a percent change
from session baseline. Intra-NAC perfusions of drugs led to differ-
ential effects on cortical ACh efflux (GROUP, F2,14 ¼ 8.652,
P ¼ 0.005). These effects varied across collection interval (TIME,
F12,84 ¼ 5.958, P < 0.001; GROUP · TIME, F24,168 ¼ 3.231,
P ¼ 0.001). Considering the overall main effects comparing all three
treatment groups, a series of smaller two-way anovas was conducted
to look for differences between pairs of treatment groups. Adminis-
tration of 150 lm NMDA significantly increased ACh levels above
the vehicle aCSF session (GROUP, F1,7 ¼ 11.655, P ¼ 0.011; TIME,
F12,84 ¼ 4.853, P < 0.001; GROUP · TIME, F12,84 ¼ 4.591,
P < 0.001). NMDA was significantly higher than aCSF within the
first 15 min of perfusion (collection 7, t7 ¼ )4.705, P ¼ 0.002), and
levels became comparable between the two treatment groups by the
end of the 60-min perfusion period (collection 10, t7 ¼ )1.470,
P ¼ 0.185). Moreover, ACh levels from collection 10, in both
treatment groups, were no longer elevated above their respective
baseline values.
Co-administration of a D1 antagonist attenuated the NMDA-
induced increases in ACh, as efflux following 150 lm NMDA
differed significantly from that seen following 150 lm SCH-
23390 + 150 lm NMDA (GROUP, F1,7 ¼ 7.025, P ¼ 0.033; TIME,
F12,84 ¼ 6.197, P < 0.001; GROUP · TIME, F12,84 ¼ 2.289,
P ¼ 0.038). The D1 antagonist suppressed NMDA-induced levels
during collection 7 and 8 (both P < 0.05). The D1 attenuation of the
NMDA effect is also supported by the observation that 150 lm SCH-
23390 + 150 lm NMDA did not differ from the vehicle aCSF session
(GROUP, F1,7 ¼ 3.395, P ¼ 0.108), although there was an effect of
TIME (F12,84 ¼ 2.751, P ¼ 0.003) and a GROUP–TIME interaction
(F12,84 ¼ 2.320, P ¼ 0.013). The D1 receptor-mediated attenuation
seen following co-administration of NMDA + D1 antagonist was not
complete. Administration of NMDA + SCH-23390 yielded significant
increases, above the aCSF vehicle session, during collections 8 and 9
(corresponding to 30 and 45 min of double drug perfusion). ACh
efflux following perfusion of the antagonist alone (collections 5 and 6)
did not differ from any of the baseline points (all P > 0.05), indicating
that perfusion of D1 antagonist alone did not affect ACh release.
Finally, in a separate group of animals (n ¼ 4) we determined the
effects of SCH-23390 perfusions throughout the period during which
NMDA + SCH-23390 were perfused. There was no significant
deviation of ACh efflux from the aCSF control condition as the mean
(SEM) efflux (% change from baseline) was )6.5 ± 5.3 (F12 ¼ 0.641,
P ¼ 0.793). These data are represented as dotted lines in Figs 2 and 3.
Experiment 2: the effects of a D1 antagonist on a higher
concentration of NMDA
This experiment determined whether D1 receptor activity contributed
to the ability of a higher concentration of NMDA to stimulate cortical
Fig. 2. Mean (± SEM) acetylcholine (ACh) efflux in the mPFC of animals (n ¼ 8) receiving, in counterbalanced order, vehicle (artificial cerebrospinal fluid,
aCSF), a moderate concentration of N-methyl-d-aspartate (NMDA) alone (150 lm), and co-administration of a D1 antagonist SCH-23390 + NMDA into the NAC
shell during three separate dialysis sessions. Following baseline collections (collections 1–4), vehicle or the antagonist was administered for 30 min (collections
5–6). This was followed by administration of aCSF + drug (vehicle, NMDA, or SCH-23390 + NMDA) for 60 min (collections 7–10). Upon conclusion of the
60-min perfusion, aCSF alone was perfused for 45 min until the end of the dialysis period (collections 11–13). NMDA alone significantly increased ACh efflux
above vehicle, and co-administration of the D1 antagonist SCH-23390 + NMDA partially, though significantly, attenuated the effect of the moderate concentration of
NMDA. A separate group of animals was tested as time-controls for the prolonged effects of perfusion of SCH-23390 (dotted line). It is clear that the extended
perfusion of the D1 antagonist had no effect on cortical ACh efflux, indicating that the effect of SCH-23390 was in interaction with the administration of NMDA.
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ACh efflux as it does following a more moderate concentration of
NMDA (Experiment1). Figure 3 illustrates the effects of 250 lm
NMDA and 150 lm SCH-23390 + 250 lm NMDA on cortical ACh
efflux (n ¼ 9). Basal levels of ACh efflux were stable over both
SESSIONs (F2,16 ¼ 0.052, P ¼ 0.950), and treatment GROUPs
(F2,16 ¼ 3.089, P ¼ 0.073), as shown by a one-way anova. Basal
levels of ACh (mean ± SEM, fmol ⁄ 15 lL) were 7.1 ± 1.7, 4.9 ± 0.8
and 10.3 ± 1.9 for aCSF, 250 lm NMDA, and the 150 lm SCH-
23390 + 250 lm NMDA sessions, respectively. Given that basal
levels of ACh efflux did not differ over session or group, all values
were expressed as a percent change from session baseline. An overall
analysis revealed significant differences among treatment groups and
collection intervals (GROUP, F2,16 ¼ 13.986, P < 0.001; TIME,
F12,96 ¼ 9.674, P < 0.001; GROUP · TIME, F24,192 ¼ 2.987,
P < 0.001).
A series of smaller two-way anovas was conducted to look for
differences between pairs of treatment groups. Administration of
250 lm NMDA significantly elevated ACh levels above aCSF levels
(GROUP, F1,8 ¼ 33.164, P < 0.001; TIME, F12,96 ¼ 8.533,
P < 0.001; GROUP · TIME, F12,96 ¼ 5.522, P < 0.001). Pairwise
comparisons revealed NMDA-induced increases in ACh efflux during
collections 7, 8 and 9 (all P < 0.05). As was the case with the lower
concentration, ACh levels fell to control aCSF values despite the
continued perfusion of NMDA during collection 10.
Three analyses support the conclusion that co-perfusion of the D1
antagonist did not attenuate the ability of the higher concentration of
NMDA to stimulate ACh efflux. First, overall ACh efflux from
NMDA alone did not differ from efflux induced by administration of
the NMDA + SCH-23390 (GROUP, F1,8 ¼ 3.883, P ¼ 0.084).
Second, administration of 150 lm SCH-23390 + 250 lm NMDA
significantly elevated ACh efflux above aCSF levels (GROUP,
F1,8 ¼ 8.405, P ¼ 0.020). Levels from both 250 lm NMDA alone
and 250 lm NMDA + 150 lm SCH-23390 were significantly higher
than those following aCSF beginning at the first post-drug time point
(collection 7, both P < 0.01), but did not differ from one another
(t8 ¼ 0.494, P ¼ 0.635). By the end of the 60-min perfusion period,
there were no significant differences among any of the drug treatments
(collection 10, all P > 0.05). Finally, administration of
NMDA + SCH-23390 (TIME, F12,96 ¼ 4.048, P ¼ 0.001) yielded
significant increases relative to baseline values in this group (all
P < 0.05). Importantly, perfusion of the antagonist alone (collections 5
and 6) yielded no increases above any of the baseline points (all
P > 0.05), indicating the antagonist alone did not differentially
influence ACh release.
Discussion
The aim of these studies was to test the capacity of D1 receptors in the
NAC to positively modulate local glutamate activity based on the
degree of NMDA receptor activation, and to determine whether this
modulation could be shown trans-synaptically at the level of ACh
release in mPFC. Several major findings can be reported. First, intra-
accumbens administration of either 150 lm or 250 lm concentration
of NMDA significantly elevated ACh efflux above baseline in the
mPFC. Second, the D1 receptor antagonist SCH-23390 significantly,
though not completely, attenuated the effect of the lower concentration
of NMDA, supporting the hypothesis of D1 receptor activity as a
Fig. 3. Mean (± SEM) acetylcholine (ACh) efflux in the mPFC of animals (n ¼ 9) receiving, in counterbalanced order, vehicle (artificial cerebrospinal fluid,
aCSF), a high concentration of N-methyl-d-aspartate (NMDA) alone (250 lm), and co-administration of a D1 antagonist SCH-23390 + NMDA into the NAC shell
during three separate dialysis sessions. Following baseline collections (collections 1–4), vehicle or the antagonist was administered for 30 min (collections 5–6). This
was followed by administration of aCSF + drug (vehicle, NMDA, or SCH-23390 + NMDA) for 60 min (collections 7–10). Upon conclusion of the 60-min
perfusion, aCSF alone was perfused for 45 min until the end of the dialysis period (collections 11–13). NMDA alone significantly increased ACh efflux above
vehicle. Unlike the case with 150 lm NMDA, co-administration of the D1 antagonist SCH-23390 + 250 lm NMDA did not attenuate the effect of the high
concentration of NMDA. A separate group of animals was tested as time-controls for the prolonged effects of perfusion of SCH-23390 (dotted line). It is clear that
the extended perfusion of the D1 antagonist had no effect on cortical ACh efflux.
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positive modulator of NMDA function. Third, the D1 antagonist was
not able to attenuate ACh efflux induced by the higher concentration
of NMDA, indicating that the contribution of D1 receptor activity may
interact with the level of NMDA receptor activation to stimulate
cortical ACh release. The following discussion will address several
issues raised by these experiments.
Intra-accumbens NMDA-induced increases in cortical ACh
Our present studies illustrate that increases in NMDA receptor activity
in the shell of the NAC are sufficient to increase ACh distally in the
mPFC. Interestingly, there were no differences between the effects of
150 lm and 250 lm concentrations of NMDA; administration of each
resulted in ACh increases approximately 150% above baseline. This
may reflect a similar degree of receptor activation produced by the two
concentrations. It is possible that the lower NMDA concentration
saturates available receptors or other transduction mechanisms. Given
that we are measuring trans-synaptic effects of NMDA receptor
stimulation, it is also possible that excitatory inputs to basal forebrain
(or locally within cortex) are similar following the perfusion of each
concentration of NMDA, and that these inputs, rather than the degree
of NMDA receptor activity, are limiting the amount of ACh released.
Pilot studies in our laboratory have revealed that perfusions of 75 lm
NMDA are insufficient to stimulate ACh efflux. We are currently
determining whether concentrations between 75 and 150 lm NMDA
will yield an elevation of ACh release that is significant but less than
that seen following 150 or 250 lm NMDA.
The NMDA-induced increase in cortical ACh release was, unex-
pectedly, seen under baseline conditions. This effect stands in contrast
to previous experiments with NMDA infusions into basal forebrain in
which stimulation of cortical ACh release only occurred following
concomitant activation with a behavioral stimulus (Fadel et al., 2001).
NMDA receptor activation is both ligand and voltage dependent,
which suggests that additional sources are providing local depolar-
ization in the NAC following NMDA perfusions. NMDA receptor
activation has been shown to be dependent on depolarization by
AMPA and metabotropic glutamate receptors (Hu & White, 1998;
Taverna & Pennartz, 2003), though there may be influences other than
glutamate impacting NMDA activity as well. For example, intra-
accumbens activation of DA receptors increases glutamate transmis-
sion (Dalia et al., 1998), and this may serve as a source of necessary
depolarization.
The neuronal circuitry underlying the ability of NMDA receptors in
NAC to stimulate ACh release in PFC is presently unknown. A priori,
there are several possibilities. As discussed in the Introduction,
NMDA (and dopamine) receptors modulate the firing rates of
GABAergic projections, which in turn regulate the excitability of
basal forebrain neurons (Mogenson et al., 1983). Basal forebrain
neurons can then regulate cortical ACh release directly via cholinergic
projections from substantia innominata to the entire neocortical mantle
(Zaborszky et al., 1999; Semba, 2000). The basal forebrain can also
affect cortical ACh release indirectly via a ventral pallidal–thalamo-
cortical circuit (Maurice et al., 1997). Local increases in AMPA
receptor activity have recently been shown to increase ACh release in
prefrontal and posterior parietal cortex (Nelson et al., 2005), and this
glutamate receptor activity could arise, in part, from thalamic inputs.
NAC efferents could also indirectly affect cortical ACh release via
recurrent projections to the VTA. The VTA could then, in turn,
influence basal forebrain excitability via dopaminergic projections to
PFC (Seamans & Yang, 2004). In this regard, local D1 receptor
activity has recently been shown to modulate ACh efflux in PFC
(Laplante et al., 2004). We are currently conducting experiments to
assess the relative contributions of basal forebrain and VTA in the
stimulatory affects of accumbens NMDA on cortical ACh efflux. We
are also conducting control experiments to determine whether
diffusion of NMDA out of the shell to other regions of the NAC or
dorsal striatum would be sufficient to stimulate cortical ACh release,
although the efferent projections of the shell to both the basal
forebrain and the VTA make perfusions in this area the likely locus of
action.
Antagonism of D1 receptors interacts with the concentration
of NMDA
Although there may be a lack of dose responsivity between the two
concentrations of NMDA, differences are seen when considering each
concentration’s interaction with the D1 antagonist. Differential
interactions between NMDA and SCH-23390 were very clear, as
administration of SCH-23390 significantly attenuated the NMDA-
induced increase from the lower concentration of NMDA, but had no
effect on ACh efflux following the higher concentration of NMDA.
Local NMDA receptor activity has been shown to stimulate dopamine
release within NAC (Grace, 1991; Floresco et al., 2001; Howland
et al., 2002), and this may contribute to the ability of D1 receptor
activity to modulate the effects of NMDA on cortical ACh release.
While the mechanisms remain to be specified, our present data suggest
that the higher concentration of NMDA was sufficient to stimulate
NAC efferents regulating ACh release, whereas the lower concentra-
tion required some positive modulation by D1 receptors in order to
achieve much of its impact on cortical ACh release. It remains
possible, however, that a higher concentration of SCH-23390 might be
required to attenuate the effects of 250 lm NMDA. However, 100 lm
of SCH-23390 has been recently shown to attenuate the ability of
perfused NMDA (250 lm) to stimulate locomotor behavior and local
dopamine release (Zornoza et al., 2005). It also remains possible,
although not likely, that the effects of SCH-23390 reflected the drug’s
ability to affect 5HT receptors (Alburges et al., 1992; Millan et al.,
2001). A test of this hypothesis will require the use of a more selective
D1 receptor antagonist.
The exact mechanisms underlying the cooperativity between D1
receptor activity and the lower concentration of NMDA in modulating
cortical ACh release are yet to be determined. It is certainly possible
that this cooperative interaction begins at the level of common NAC
efferents. NAC medium spiny projection neurons contain ionotropic
(NMDA, AMPA ⁄ kainate) and metabotropic glutamate receptors, as
well as D1, D2, D3 and D4 receptors (Jongen-Relo et al., 1995; Tarazi
et al., 1998; Lu et al., 1999). These inputs converge in close proximity
to one another on the dendrites of NAC medium spiny projection
neurons (Sesack & Pickel, 1990). Such a dense innervation allows for
rich and complex interactions between glutamate and dopamine in the
NAC. The cooperative modulation seen in this experiment is consistent
with a number of other studies that have characterized NAC D1 and
NMDA interactions at several levels of analysis. At the level of
receptor-linked transduction mechanisms, D1 receptors regulate the
affinity of the NMDA receptor by increasing the phosphorylation and
decreasing the dephosphorylation (via a PKA ⁄DARP-32 ⁄ PP-1 path-
way) of the NR1 subunit of the NMDA receptor (Snyder et al., 1998).
D1 receptors have also been shown to regulate the trafficking of
NMDA receptors in striatum (Dunah & Standaert, 2001) and also
AMPA receptors in NAC (Chao et al., 2002). In hippocampus, there is
evidence of an even more direct D1–NMDA receptor interaction as D1
receptors are involved in the inhibition of NMDA-mediated excito-
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toxicity via actions on NMDA-gated currents (Lee et al., 2002). At the
level of target cell excitability, D1 receptors potentiate NMDA-
mediated excitation of medium spiny projection neurons in dorsal
striatum (see Cepeda & Levine, 1998 for review) and in NAC (Goto &
O’Donnell, 2001a,b; West & Grace, 2002; Charara & Grace, 2003;
O’Donnell, 2003). Finally, positive interactions between D1 and
NMDA receptors have been demonstrated at the level of locomotor
activity, instrumental responding and conditioned reinforcement
(Burns et al., 1994; Smith-Roe & Kelley, 2000).
The complexities of accumbens glutamate receptor mediation
of cortical ACh release
The ability of NMDA receptor activation to increase cortical ACh
efflux is surprising given a recent report from our laboratory
demonstrating that blockade of ionotropic glutamate receptors
(NMDA and ⁄ or AMPA ⁄ kainate) in the NAC increased ACh release
in PFC (Neigh-McCandless et al., 2002). Importantly, these iGluR
antagonists were perfused through similar probes directed at identical
coordinates as in the present study. Thus, the seemingly contradictory
results do not likely reflect methodological differences. An inspection
of the literature reveals other reports of apparent paradoxical
neurochemical and behavioral effects of local administration of
NMDA and NMDA antagonists. For example, intra-NAC infusions
of both NMDA (Svensson et al., 1994) and NMDA antagonists (Ault
& Werling, 1999) have been reported to increase local dopamine
release. At the behavioral level, locomotor activity is enhanced
following intra-NAC infusions of either NMDA (Svensson et al.,
1994; David et al., 2004) or NMDA antagonists (Kelley & Throne,
1992; David et al., 2004).
The puzzling results of our experiments on NMDA mediation of
cortical ACh release, and the above studies on dopamine release or
locomotor activity, are only contradictory if one presumes that the
infused or perfused drugs are acting at precisely the same receptors.
While possible, the likelihood that multiple receptors (subtypes with
different NR2 compositions) located on several populations of NAC
neurons (e.g. interneurons, medium spiny projection neurons to basal
forebrain or to VTA) are differentially stimulated by bolus or perfused
administration of NMDA agonists and antagonists is considerable.
With respect to our finding that both NMDA and CPP stimulate
cortical ACh release, we are currently testing the hypothesis that
NMDA agonists and antagonists exert similar effects on cortical
cholinergic transmission via their influence on different populations of
NAC interneurons or efferents that directly or indirectly regulate
cortical ACh release (see above).
Functional implications
The NAC has long been shown to be critical as an integrator of limbic
and motor information (Kelley, 1999), in reward circuits (see
Deadwyler et al., 2004) and in the attribution of incentive salience
(Berridge & Robinson, 1998). In these roles, it seems appropriate that
information processing within the NAC influences both motor output
and cognitive processes. The ability of NAC efferents to modulate
motor output has been well documented over the past several decades
(for review, see Tzschentke & Schmidt, 2000). In addition, the
convergence of excitatory information from cortex, hippocampus and
amygdala in NAC has also become the focus of recent studies
(Groenewegen et al., 1999; O’Donnell, 1999; Grace, 2000). It is vital
that this convergence of information then modulates the detection and
selection of subsequent stimuli for processing, and this involves the
recruitment of attentional resources. The ability of dopaminergic and
glutamatergic transmission in NAC to modulate cortical ACh release
may be a chemoanatomical representation of such recruitment.
In conclusion, the present studies demonstrate that D1 receptors are
stimulated following perfusion of NMDA into the NAC and that this
stimulation contributes significantly to the ability of certain concen-
trations of NMDA to increase cortical ACh release. As such, these
findings contribute to a large body of data revealing a positive
modulation of NMDA receptors by D1 receptors in NAC. The novelty
of the present study is the demonstration that this modulation is
expressed trans-synaptically at the level of cholinergic transmission
within the PFC. Further research is required to uncover the
complexities of these interactions, and to determine the contribution
of these interactions to the allocation of attention and the processing of
behaviorally relevant stimuli.
Acknowledgements
This research was supported by the following grants: MH57436, MH63114,
NS37026 and KO2MH10172.
Abbreviations
ACh, acetylcholine; aCSF, artificial cerebrospinal fluid; GABA, c-aminobutyric
acid; HPLC, high-performance liquid chromatography; NAC, nucleus accum-
bens; NMDA, N-methyl-d-aspartate; PFC, prefrontal cortex; TTX, tetrodotoxin;
VTA, ventral tegmental area.
References
Alburges, M.E., Hunt, M.E., McQuade, R.D. & Wamsley, J.K. (1992) D1-
receptor antagonists: comparison of [3H]SCH39166 to [3H]SCH23390.
J. Chem. Neuroanat., 5, 357–366.
Arnold, H.M., Burk, J.A., Hodgson, E.M., Sarter, M. & Bruno, J.P. (2002)
Differential cortical acetylcholine release in rats performing a sustained
attention task versus behavioral control tasks that do no explicitly tax
attention. Neuroscience, 114, 451–460.
Ault, D.T. & Werling, L.L. (1999) Phencyclidine and dizocilpine modulate
dopamine release from nucleus accumbens via sigma receptors. Eur. J.
Pharmacol., 386, 145–153.
Berridge, K.C. & Robinson, T.E. (1998) What is the role of dopamine in
reward: hedonic impact, reward learning, or incentive salience? Brain Res.
Brain Res. Rev., 28, 309–369.
Bruno, J.P., Sarter, M., Arnold, H.M. & Himmelheber, A.M. (1999) In vivo
neurochemical markers of cognitive processes: methodological and con-
ceptual challenges. Rev. Neurosci., 10, 25–49.
Burns, L.H., Everitt, B.J., Kelley, A.E. & Robbins, T.W. (1994) Glutamate–
dopamine interactions in the ventral striatum: role in locomotor activity and
responding with conditioned reinforcement. Psychopharmacology, 115,
516–528.
Cepeda, C. & Levine, M.S. (1998) Dopamine and m-methyl-d-aspartate
receptor interactions in the neostriatum. Dev. Neurosci., 20, 1–18.
Chao, S.Z., Ariano, M.A., Peterson, D.A. & Wolf, M.E. (2002) D1 dopamine
receptor stimulation increases GluR1 surface expression in nucleus
accumbens neurons. J. Neurochem., 83, 704–712.
Charara, A. & Grace, A.A. (2003) Dopamine receptor subtypes selectively
modulate excitatory afferents from the hippocampus and amygdala to
rat nucleus accumbens neurons. Neuropsychopharmacology, 28, 1412–
1421.
Chen, K.C., Baxter, M.G. & Rodefer, J.S. (2004) Central blockade of
muscarinic cholinergic receptors disrupts affective and attentional set-
shifting. Eur. J. Neurosci., 20, 1081–1088.
Chudasama, Y., Dalley, J.W., Nathwani, F., Bouger, P. & Robbins, T.W. (2004)
Cholinergic modulation of visual attention and working memory: dissociable
effects of basal forebrain 192-IgG-saporin lesions and intraprefrontal
infusions of scopolamine. Learn. Mem., 11, 78–86.
Dalia, A., Uretsky, N.J. & Wallace, L.J. (1998) Dopaminergic agonists
administered into the nucleus accumbens: effects on extracellular glutamate
and on locomotor activity. Brain Res., 788, 111–117.
1738 A. Zmarowski et al.
ª 2005 Federation of European Neuroscience Societies, European Journal of Neuroscience, 22, 1731–1740
Dalley, J.W., Cardinal, R.N. & Robbins, T.W. (2004a) Prefrontal executive and
cognitive functions in rodents: neural and neurochemical substrates.
Neurosci. Biobehav. Rev., 28, 771–784.
Dalley, J.W., McGaughy, J., O’Connell, M.T., Cardinal, R.N., Levita, L. &
Robbins, T.W. (2001) Distinct changes in cortical acetylcholine and
noradrenaline efflux during contingent and noncontingent performance of a
visual attentional task. J. Neurosci., 21, 4908–4914.
Dalley, J.W., Theobald, D.E., Bouger, P., Chudasama, Y., Cardinal, R.N. &
Robbins, T.W. (2004b) Cortical cholinergic function and deficits in visual
attentional performance in rats following 192 IgG-saporin-induced lesions of
the medial prefrontal cortex. Cereb. Cortex, 14, 922–932.
David, H.N., Kheira, S. & Abraini, J.H. (2004) Modulation of locomotor
responses induced by D1-like and D2-like dopamine receptor agonists and
d-amphetamine by NMDA and non-NMDA glutamate receptor agonists and
antagonists in the core of the rat nucleus accumbens. Neuropsychopharma-
cology, 46, 179–191.
Deadwyler, S.A., Hayashizaki, S., Cheer, J. & Hampson, R.E. (2004) Reward,
memory, and substance abuse: functional neuronal circuits in the nucleus
accumbens. Neurosci. Biobehav. Rev., 27, 703–714.
Del Arco, A. & Mora, F. (2001) Dopamine release in the prefrontal cortex
during stress is reduced by the local activation of glutamate receptors. Brain
Res. Bull., 15, 125–130.
Dunah, A.W. & Standaert, D.G. (2001) Dopamine D1 receptor-dependent
trafficking of striatal NMDA glutamate receptors to the postsynaptic
membrane. J. Neurosci., 21, 5546–5558.
Fadel, J., Sarter, M. & Bruno, J.P. (2001) Basal forebrain glutamatergic
modulation of cortical acetylcholine release. Synapse, 39, 201–212.
Floresco, S.B., Todd, C.L. & Grace, A.A. (2001) Glutamatergic afferents from
the hippocampus to the nucleus accumbens regulate activity of ventral
tegmental area dopamine neurons. J. Neurosci., 21, 4915–4922.
Franken, I.H. (2003) Drug craving and addiction: integrating psychological and
neuropsychopharmacological approaches. Prog. Neuropsychopharmacol.
Biol. Psychiatry, 27, 563–579.
Ghitza, U.E., Fabbricatore, A.T., Prokopenko, V.F. & West, M.O. (2004)
Differences between accumbens core and shell neurons exhibiting phasic
firing patterns related to drug seeking behavior during discriminative-
stimulus task. J. Neurophysiol., 93, 1608–1614.
Goto, Y. & O’Donnell, P. (2001a) Synchronous activity in the hippocampus and
nucleus accumbens in vivo. J. Neurosci., 24, 121–131.
Goto, Y. & O’Donnell, P. (2001b) Network synchrony in the nucleus
accumbens in vivo. J. Neurosci., 27, 4498–4504.
Grace, A.A. (1991) Phasic versus tonic dopamine release and the modulation of
dopamine system responsivity: a hypothesis for the etiology of schizophre-
nia. Neuroscience, 41, 1–24.
Grace, A.A. (2000) Gating of information flow within the limbic system and
the pathophysiology of schizophrenia. Brain Res. Rev., 31, 330–341.
Groenewegen, H.J., Mulder, A.B., Beijer, A.V.J., Wright, C.I., Lopes da Silva,
F.H. & Pennartz, C.M.A. (1999) Hippocampal and amygdaloid interactions
in the nucleus accumbens. Psychobiology, 27, 149–164.
Hahn, B., Sarples, C.G.V., Wonnacott, S., Shoaib, M. & Stolerman, I.P. (2003)
Attentional effects of nicotinic agonists in rats. Neuropharmacology, 44,
1054–1067.
Himmelheber, A.M., Sarter, M. & Bruno, J.P. (2000) Increases in cortical
acetylcholine release during sustained attention performance in rats. Cogn.
Brain Res., 9, 313–325.
Howland, J.G., Taepavarapruk, P. & Phillips, A.G. (2002) Glutamate receptor-
dependent modulation of dopamine efflux in the nucleus accumbens by
basolateral, cut not central, nucleus of the amygdale in rats. J. Neurosci., 22,
1137–1145.
Hu, X. & White, F.J. (1998) Glutamate receptor regulation of rat nucleus
accumbens neurons in vivo. Synapse, 23, 208–218.
Huang, T., Yang, L., Gitzen, J., Kissinger, P.T., Vreeke, M. & Heller, A. (1995)
Detection of basal acetylcholine in rat brain microdialysate. J. Chromatogr.,
670, 323–327.
Jongen-Relo, A.L., Docter, G.J., Jonke, R.A.J. & Voorn, P. (1995) Differential
localization of mRNAs encoding dopamine D1 or D2 receptors in
cholinergic neurons in the core and shell of the rat nucleus accumbens.
Brain Res. Mol. Brain Res., 28, 169–174.
Kelley, A.E. (1999) Neural integrative activities of nucleus accumbens subre-
gions in relation to learning and motivation. Psychobiology, 27, 198–213.
Kelley, A.E. & Throne, L.C. (1992) NMDA receptors mediate the behavioral
effects of amphetamine infused into the nucleus accumbens. Brain Res. Bull.,
29, 247–254.
Koller, G., Satzger, W., Adam, M., Wagner, M., Kathmann, N., Soyka, M.
& Engel, R. (2003) Effects of scopolamine on matching to sample
paradigm and related tests in human subjects. Neuropsychobiology, 48,
87–94.
Kozak, R., Bruno, J.P. & Sarter, M. (2005) Augmentation of attentional
performance-associated increases in prefrontal acetylcholine release during
basal forebrain NMDA receptor blockade-induced impairments in perform-
ance. Cereb. Cortex., in press.
Kumari, V., Gray, J.A., ffytche, D.H., Mitterschiffthaler, M.T., Das, M.,
Zachariah, E., Vythelingum, G.N., Williams, S.C.R., Simmons, A. &
Sharma, T. (2003) Cognitive effects of nicotine in humans: an fMRI study.
Neuroimage, 19, 1002–1013.
Laplante, F., Srivastava, L.K. & Quirion, R. (2004) Alterations in
dopaminergic modulation of prefrontal cortical acetylcholine release in
post-pubertal rats with neonatal ventral hippocampal lesions. J. Neurochem.,
89, 314–323.
Lee, F.J.S., Xue, S., Pei, L., Vukusic, B., Chery, N., Wang, Y., Wang, Y.T. &
Niznik, H.B., Yu, X. & Liu, F. (2002) Dual regulation of NMDA receptor
functions by direct protein–protein interactions with the dopamine D1
receptor. Cell, 111, 219–230.
Legault, M. & Wise, R.A. (1999) Injections of n-methyl-d-aspartate into the
ventral hippocampus increase extracellular dopamine in the ventral
tegmental area and nucleus accumbens. Synapse, 31, 241–249.
Lorrain, D.S., Baccei, C.S., Bristow, L.J., Anderson, J.J. & Varney, M.A.
(2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and
dopamine release in the rat prefrontal cortex: modulation by a group II
selective metabotropic glutamate receptor agonist LY379268. Neuroscience,
117, 697–706.
Lu, X.Y., Chasemzadeh, M.B. & Kalivas, P.W. (1999) Expression of glutamate
receptor subunit ⁄ subtype messenger RNAS for NMDAR1, GluR1, GluR2
and mGLuR5 by accumbal projection neurons. Mol. Brain Res., 63, 287–
296.
Marti, M., Mela, F., Bianchi, C., Beani, L. & Morari, M., (2002) Striatal
dopamine–NMDA receptor interactions in the modulation of glutamate
release in the substantia nigra pars reticulate in vivo: opposite role for D1 and
D2 receptors. J. Neurochem., 83, 635–644.
Mauri, M., Sinforiani, E., Reverberi, F., Merlo, P. & Bono, G. (1994)
Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers.
Arch. Gerontol. Geriatr., 18, 133–139.
Maurice, N., Deniau, J.M., Menetrey, A., Glowinski, J. & Thierry, A.M. (1997)
Position of the ventral pallidum in the rat prefrontal cortex-basal ganglia
circuit. Neuroscience, 80, 523–534.
McGaughy, J., Kaiser, T. & Sarter, M. (1996) Behavioral vigilance following
infusions of 192 IgG-saporin into the basal forebrain: selectivity of the
behavioral impairment and relation to cortical AchE-positive fiber density.
Behav. Neurosci., 110, 247–265.
Millan, M.J., Newman-Tancredi, A., Quentric, Y. & Cussac, D. (2001) The
selective dopamine D1 receptor antagonist, SCH 23390, is a potent and high
efficacy agonist at cloned human serotonin2C receptors. Psychopharmacol-
ogy, 156, 58–62.
Mogenson, G.J., Jones, D.L. & Yim, C.Y. (1980) From motivation to action:
functional interface between the limbic system and the motor system. Prog.
Neurobiol., 14, 69–97.
Mogenson, G.J., Swanson, L.W. & Wu, M. (1983) Neural projections from
nucleus accumbens to globus pallidus, substantia innominata, and lateral
preoptica-lateral hypothalamic area: an anatomical and electrophysiological
investigation in the rat. J. Neurosci., 1, 189–202.
Mogenson, G.J. & Yang, C.R. (1991) The contribution of basal forebrain to
limbic-motor integration and the mediation of motivation to action. Adv. Exp.
Med. Biol., 295, 267–290.
Moore, H., Fadel, J., Sarter, M. & Bruno, J.P. (1999) Role of accumbens and
cortical dopamine receptors in the regulation of cortical acetylcholine
release. Neuroscience, 88, 811–822.
Moore, H., Sarter, M. & Bruno, J.P. (1992) Age-dependent modulation of in
vivo cortical acetylcholine release by benzodiazepine receptor ligands. Brain
Res., 596, 7–29.
Neigh, G.N., Arnold, H.M., Rabenstein, R.L., Sarter, M. & Bruno, J.P. (2004)
Neuronal activity in the nucleus accumbens is necessary for performance-
related increases in cortical acetylcholine release. Neuroscience, 123, 635–
645.
Neigh-McCandless, G., Kravitz, B.A., Sarter, M. & Bruno, J.P. (2002)
Ionotropic glutamate receptor blockade in the nucleus accumbens increases
cortical acetylcholine release. Eur. J. Neurosci., 16, 1259–1266.
Nelson, C.L., Burk, J.A., Bruno, J.P. & Sarter, M. (2002) Effects of acute and
repeated systemic administration of ketamine on prefrontal acetylcholine
release and sustained attention performance in rats. Psychopharmacology,
161, 168–179.
NMDA and dopamine interactions 1739
ª 2005 Federation of European Neuroscience Societies, European Journal of Neuroscience, 22, 1731–1740
Nelson, C.L., Sarter, M. & Bruno, J.P. (2005) Prefrontal cortical modulation of
acetylcholine release in posterior parietal cortex. Neuroscience, 132, 347–
359.
Nicola, S.M., Yun, I.A., Wakabayashi, K.T. & Fields, H.L. (2004a) Cue-evoked
firing of nucleus accumbens neurons encodes motivational significance
during a discriminative stimulus task. J. Neurophysiol., 91, 1840–1865.
Nicola, S.M., Yun, I.A., Wakabayashi, K.T. & Fields, H.L. (2004b) Firing of
nucleus accumbens neurons during the consummatory phase of a
discriminative stimulus task depends on previous reward predictive cues.
J. Neurophysiol., 91, 1866–1882.
O’Donnell, P. (1999) Ensemble encoding in the nucleus accumbens. Psycho-
biology, 27, 187–197.
O’Donnell, P. (2003) Dopamine gating of forebrain neural ensembles. Eur. J.
Neurosci., 17, 429–435.
Passetti, F., Dalley, J.W., O’Connell, M.T., Everitt, B.J. & Robbins, T.W.
(2000) Increased acetylcholine release in the rat medial prefrontal cortex
during performance of a visual attentional task. Eur. J. Neurosci., 12,
3051–3058.
Paxinos, G. & Watson, C. (1998) The Rat Brain in Stereotaxic Coordinates.
Academic Press, New York.
Pennartz, C.M.A., Groenewegen, H.J. & Lopes da Silva, F.H. (1994) Nucleus
accumbens as a complex of functionally distinct neuronal ensembles: an
integration of behavioural, electrophysiological and anatomical data. Progess
Neurobiol., 42, 719–761.
Potter, P.E., Meek, J.L. & Neff, N.H. (1983) Acetylcholine and choline in
neuronal tissue measured by HPLC with electrochemical detection.
J. Neurochem., 41, 188–194.
Rebec, G.W., Grabner, C.P., Johnson, M., Pierce, R.C. & Bardo, M.T.
(1997) Transient increases in catecholaminergic activity in medial
prefrontal cortex and nucleus accumbens shell during novelty.
Neuroscience, 76, 707–714.
Sarter, M., Bruno, J.P. & Givens, B. (2003) Attentional function of cortical
cholinergic inputs: what does it mean for learning and memory? Neurobiol.
Learn. Mem., 80, 245–256.
Sarter, M., Givens, B. & Bruno, J.P. (2001) The cognitive neuroscience of
sustained attention: where top-down meets bottom-up. Brain Res. Rev., 35,
146–160.
Schoenbaum, G., Chiba, A.A. & Gallagher, M. (1998) Orbitofrontal cortex and
basolateral amygdala encode expected outcomes during learning. Nat.
Neurosci., 1, 155–159.
Schoenbaum, G., Chiba, A.A. & Gallagher, M. (1999) Neural encoding in
orbitofrontal cortex and basolateral amygdala during olfactory discrimination
learning. J. Neurosci., 19, 1876–1884.
Schultz, W., Tremblay, K. & Hollerman, J.R. (2003) Changes in behavior-
related neuronal activity in the striatum during learning. Trends Neurosci.,
26, 321–328.
Seamans, J.K. & Yang, C.R. (2004) The principal features and mechanisms of
dopamine modulation in the prefrontal cortex. Prog. Neurobiol., 74, 1–58.
Semba, K. (2000) Multiple output pathways of the basal forebrain: organiza-
tion, chemical heterogeneity, and roles in vigilance. Behav. Brain Res., 115,
117–141.
Sesack, S.R. & Pickel, V.M. (1990) In the rat medial nucleus accumbens,
hippocampal and catecholaminergic terminals converge on spiny neurons
and are in opposition to each other. Brain Res., 527, 266–279.
Smith-Roe, S.L. & Kelley, A.E. (2000) Coincident activation of NMDA and
dopamine D1 receptors within the nucleus accumbens core is required for
appetitive instrumental learning. J. Neurosci., 20, 7737–7742.
Snyder, G.L., Fienberg, A.A., Huganir, R.L. & Greengard, P. (1998) A
dopamine ⁄D1 receptor ⁄ protein kinase A ⁄ dopamine- and cAMP- regulated
phosphoprotein (Mr 32 kDa) ⁄ protein phosphatase-1 pathway regulates
dephosphorylation of the NMDA receptor. J. Neurosci., 18, 10297–10303.
Svensson, L., Zhang, J., Johannessen, K. & Engel, J.A. (1994) Effect of local
infusion of glutamate analogues into the nucleus accumbens of rats: an
electrochemical and behavioural study. Brain Res., 643, 155–161.
Tarazi, F.I., Campbell, A., Yeghiayan, S.K. & Baldessarini, R.J. (1998)
Localization of ionotropic glutamate receptors in caudate-putamen and
nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and
kainate receptors. Synapse, 30, 227–235.
Taverna, S. & Pennartz, C.M.A. (2003) Postsynaptic modulation of AMPA-
and NMDA-receptor currents by Group III metabotropic glutamate receptors
in rat nucleus accumbens. Brain Res., 976, 60–68.
Tzschentke, T.M. & Schmidt, W.J. (2000) Functional relationship among
medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in
locomotion and reward. Crit. Rev. Neurobiol., 14, 131–142.
Vasey, M.W. & Thayer, J.F. (1987) The continuing problem of false positives in
repeated measures anova in psychophysiology: a multivariate solution.
Psychophysiology, 24, 479–486.
Vezina, P. & Kim, J.H. (1999) Metabotropic glutamate receptors and the
generation of locomotor activity: interactions with midbrain dopamine.
Neurosci. Biobehav. Rev., 23, 577–589.
West, A.R. & Grace, A.A. (2002) Opposite influences of endogenous dopamine
D1 and D2 receptor activation on activity states and electrophysiological
properties of striatal neurons: studies combining in vivo intracellular
recordings and reverse microdialysis. J. Neurosci., 22, 294–304.
Yun, I.A., Nicola, S.M. & Fields, H.L. (2004a) Contrasting effects of dopamine
and glutamate receptor antagonist injection in the nucleus accumbens
suggest a neural mechanism underlying cue-evoked goal-directed behavior.
Eur. J. Neurosci., 20, 249–263.
Yun, I.A., Wakabayashi, K.T., Fields, H.L. & Nicola, S.M. (2004b) The ventral
tegmental area is required for the behavioral and nucleus accumbens
neuronal firing responses to incentive cues. J. Neurosci., 24, 2923–2933.
Zaborszky, L. & Cullinan, W.E. (1992) Projections from the nucleus
accumbens to cholinergic neurons of the ventral pallidum: a correlated light
and electron microscopic double-immunolabeling study in rat. Brain Res.,
570, 92–101.
Zaborszky, L., Pang, K., Somogyi, J., Nadasdy, Z. & Kalli, I. (1999) The basal
forebrain corticopetal system revisited. Ann. NY Acad. Sci., 877, 339–367.
Zornoza, T., Cano-Cebrian, M.J., Miquel, M., Aragon, C., Polache, A. &
Granero, L. (2005) Hippocampal dopamine receptors modulate the motor
activation and the increase in dopamine levels in the rat nucleus accumbens
evoked by chemical stimulation of the ventral hippocampus. Neuropsycho-
pharmacology, 30, 843–852.
1740 A. Zmarowski et al.
ª 2005 Federation of European Neuroscience Societies, European Journal of Neuroscience, 22, 1731–1740
